RESEARCH

BMJ

Primary total hip arthroplasty versus hemiarthroplasty for displaced intracapsular hip fractures in older patients: systematic review

Colin Hopley, strategic health outcomes manager,¹ Dirk Stengel, senior clinical epidemiologist,^{2,3} Axel Ekkernkamp, professor,^{2,3} Michael Wich, professor^{2,4}

¹DePuy International, Leeds LS11 8DT

²Department of Trauma and Orthopaedic Surgery, Unfallkrankenhaus Berlin, Berlin, Germany

³Department of Trauma and Orthopaedic Surgery, Ernst Moritz Arndt University Hospital, Greifswald, Germany ⁴Alice Salomon University of Applied Sciences, Berlin, Germany

Correspondence to: C Hopley chopley@its.jnj.com

Cite this as: *BMJ* 2010;340:c2332 doi:10.1136/bmj.c2332

ABSTRACT

Objective To determine whether total hip arthroplasty is associated with lower reoperation rates, mortality, and complications, and better function and quality of life than hemiarthroplasty for displaced fractures of the femoral neck in older patients.

Design Systematic review and meta-analysis of randomised trials, quasirandomised trials, and cohort studies.

Data sources Medline, Embase, Cochrane register of controlled trials, publishers' databases, and manual search of bibliographies.

Study selection Randomised controlled trials, quasirandomised trials, and cohort studies (retrospective and prospective) comparing hemiarthroplasty with total hip arthroplasty for treating displaced femoral neck fractures in patients aged more than 60 years. Data extraction Relative risks, risk differences, and mean differences from each trial, aggregated using random effects models. Analyses were stratified for experimental and non-experimental designs, and two way sensitivity analyses and tests for interaction were done to assess the influence of various criteria of methodological quality on pooled estimates.

Data synthesis 3821 references were identified. Of the 202 full papers inspected, 15 were included (four randomised controlled trials, three guasirandomised trials, and eight retrospective cohort studies, totalling 1890 patients). Meta-analysis of 14 studies showed a lower risk of reoperation after total hip arthroplasty compared with hemiarthroplasty (relative risk 0.57, 95% confidence interval 0.34 to 0.96, risk difference 4.4%, 95% confidence interval 0.2% to 8.5%), although this effect was mainly driven by investigations without concealed treatment allocation. Total hip arthroplasty consistently showed better ratings in the Harris hip score (three studies, 246 patients, weighted mean difference 5.4, 95% confidence interval 2.7 to 8.2) after follow-up periods of 12 to 48 months. The standardised mean difference of different scores from five studies was 0.42 (95% confidence interval 0.24 to 0.61), indicating a medium functional advantage of total hip arthroplasty over hemiarthroplasty. Total hip arthroplasty was

associated with a slightly higher risk of dislocation (relative risk 1.48, 95% confidence interval 0.89 to 2.46) and general complications (1.14, 0.87 to 1.48). **Conclusion** Single stage total hip arthroplasty may lead to lower reoperation rates and better functional outcomes compared with hemiarthroplasty in older patients with displaced femoral neck fractures. However, heterogeneity across the available trials and distinct subgroup effects preclude definitive statements and require further research in this area.

INTRODUCTION

Hip fractures in older patients are associated with impaired mobility, excess morbidity and mortality, and loss of independence. With the reversing ageing pyramid and the high prevalence of osteoporosis, hip fractures remain a public health concern. Incidence estimates vary considerably among industrial countries.¹⁻⁹ Models aimed at projecting the contribution of hip fractures to the future global burden of disease produced inconclusive results,¹⁰ and depended on assumptions about the effectiveness of multifaceted interventions for preventing falls and managing osteoporosis.¹¹⁻²⁰

Typical predilection sites for fractures of the proximal femur are the femoral neck and the intertrochanteric and subtrochanteric regions. Displaced, unstable fractures of the femoral neck generally represent an indication for early surgical intervention. Established treatment options include internal fixation with cannulated or sliding hip screws, hemiarthroplasty, or total hip replacement. Well recognised goals of surgical treatment are immediate pain relief, rapid mobilisation and ambulation, accelerated rehabilitation, and maintenance of independent living. In addition to these prerequisites, the ideal implant must be associated with a low risk of surgical complications and subsequent revision. At best, patients should not be hampered by the treated hip during their remaining lifetime.

Evidence is now compelling from randomised controlled trials that, in displaced femoral neck fractures, primary arthroplasty outperforms internal fixation for complication and revision rates, function, and health

Table 1| Summary of key criteria of individual investigations

Table 1 Summary	of key criteria	of individual investigat	ions			
Study	Recruitment period	Indication	Mean duration of follow-up (months)	Treatment assignment	No of validity criteria met (out of 12)	Outcome measures recorded and analysed
3aker 2006 ⁴⁸	NS	Displaced femoral neck fractures	40	Randomised, sealed envelopes	8	Reoperations, dislocations, infections, general complications, mortality, function (Oxford hip score), quality of life (SF-36)
3lomfeldt 2007 ⁴⁹	NS	Displaced femoral neck fractures	12	Randomised, sealed envelopes	9	Reoperations, dislocations, infections, general complications, mortality, quality of life (EQ-5D)
)orr 1986 ⁵⁰	1980-2	Displaced femoral neck fractures Garden III/IV	24	Odd and even hospital number	9	Reoperations, dislocations, infections, mortality, quality of life (EQ-5D)
Eyssel 1994 ⁵²	1984-92	Displaced femoral neck fractures Garden III/IV	1	NS	7	Reoperations, dislocations, infections, general complications, mortality
Gebhard 199253	1973-86	Displaced femoral neck fractures	55	NS	6	Reoperations, dislocations, infections, general complications, mortality
lealy 2004 ⁵⁴	1993-6	Displaced femoral neck fractures Garden III/IV	71	NS	5	Reoperations, infections
Ceating 2006 ⁴⁵	1996-2000	Displaced femoral neck fractures	24	Randomised, computerised telephone service	8	Reoperations, dislocations, infections, general complications, quality of life EQ-5D
.evi 1996 ⁵⁵	1990-3	Femoral neck fractures, 97% Garden III/IV	3	NS	2	Infections, mortality
Macaulay 2008 ^{42 43}	NS	Displaced femoral neck fractures Garden III/IV	24	Randomised, opaque sealed envelopes	4	Reoperations, dislocations, infections, general complications, mortality, function (Harris hip score), quality of life (SF-36)
Nouzopoulos 2008 ⁵¹	1999-2002	Displaced femoral neck fractures Garden III/IV	48	Fixed alternating sequence	3	Reoperations, mortality, function (Harris hi score), quality of life (SF-36)
√arayan 2006 ⁵⁶	1997-2002	Displaced femoral neck fractures Garden III/IV	58	Dependent on availability	5	Reoperations, dislocations, general complications, function (Oxford hip score), quality of life (SF-36)
avikumar 2000 ⁴⁶	1984-6	Displaced femoral neck fractures Garden III/IV	156	Day of week	1	Reoperations; dislocations; infections; mortality; quality of life (EQ-5D)
Schleicher 2003 ⁵⁷	1991-4	Displaced femoral neck fractures	98	NS	4	Reoperations, dislocations, infections, general complications, mortality, function (Oxford hip score), quality of life (SF-36)
Squires 1999 ⁵⁸	NS	Displaced femoral neck fractures	46	Different treatment policy at two district general hospitals	3	Reoperations, dislocations, general complications, function (Melzer hip score)
(u 2002 ⁵⁹	1987-98	Displaced femoral neck fractures	70	NS	4	Reoperations, dislocations, infections, mortality
S-not specified						

Hemiarthroplasty is a quick and highly standardised procedure that allows for early weight bearing and recovery. However, most patients with a hip fracture have osteoarthritis, which may necessitate secondary conversion to total hip replacement, especially in active elderly people with higher physical demands. Single stage surgery with acetabular replacement seems straightforward to avoid secondary admission to hospital and operation with its possible risks and extra costs. These potential benefits, however, must be traded off against the potential harms of prolonged and more invasive surgery.

Uncertainty as to which type of endoprosthesis is the ideal choice for treatment of fractures in older patients leads to significant variation in the use of each intervention internationally.²⁵²⁶ Total hip replacement is three times more likely to be used to treat hip fractures in Sweden than it is in England and Wales, and twice as likely than in Canada.27



Fig 1 Review profile and study selection process

Table 2 Description of interventions received by each treatment group

			Total hip arthroplas	ty		Hemiarthroplasty	
Study	Design	Surgical approach	Fixation	No	Туре	Fixation	No
Baker 2006 ⁴⁸	Randomised controlled trial	Transgluteal lateral	Cemented	40	Bipolar	Cemented	41
Blomfeldt 2007 ⁴⁹	Randomised controlled trial	Modified Hardinge anterolateral	Cemented	60	Bipolar	Cemented	60
Dorr 1986 ⁵⁰	Lesser quality randomised controlled trial	Posterior	Cemented	39	NS	Cemented or uncemented	50
Eyssel 1994 ⁵²	Retrospective cohort	Transgluteal	Cemented	213	Bipolar	Cemented	150
Gebhard 199253	Retrospective cohort	NS	Cemented	44	NS	Cemented or uncemented	122
Healy 2004 ⁵⁴	Retrospective cohort	NS	Cemented	23	Unipolar or bipolar	Cemented	43
Keating 2006 ⁴⁵	Randomised controlled trial	Posterior or lateral	Cemented	69	Bipolar	Cemented	111
Levi 1996 ⁵⁵	Retrospective cohort	Posterior	Cemented	98	Unipolar	Cemented or uncemented	123
Macaulay 2008 ^{42 43}	Randomised controlled trial	Posterolateral or modified Hardinge anterolateral	Cemented or uncemented	17	Unipolar or bipolar	Cemented or uncemented	23
Mouzopoulos 2008 ⁵¹	Lesser quality randomised controlled trial	NS	Cemented	43	Bipolar	NS	43
Narayan 2006 ⁵⁶	Retrospective cohort	NS	Cemented or uncemented	29	Bipolar	Cemented or uncemented	32
Ravikumar 2000 ⁴⁶	Lesser quality randomised controlled trial	Posterolateral	Cemented	91	Unipolar	Uncemented	89
Schleicher 2003 ⁵⁷	Retrospective cohort	NS	Hybrid	54	Bipolar	NS	52
Squires 1999 ⁵⁸	Retrospective cohort	Posterolateral or modified Hardinge anterolateral	Cemented or uncemented	32	Unipolar or bipolar	Cemented or uncemented	43
Xu 2002 ⁵⁹	Retrospective cohort	Posterior	Cemented	32	Unipolar or bipolar	Cemented	24
NS=not specified.							

	No of ev No in g	ents/ roup			
	Treatment	Control	Relative risk	Weight	Relative risk
Retrospective cohort stu	dies		(95% CI)	(%)	(95% CI)
Gebhard 1992 ⁵³	1/44	12/122		5.42	0.23 (0.03 to 1.73)
Eyssel 1994 ⁵²	8/213	6/150		13.38	0.94 (0.33 to 2.65)
Squires 1999 ⁵⁸	2/32	16/43		9.34	0.17 (0.04 to 0.68)
Xu 2002 ⁵⁹	1/32	1/24		3.24	0.75 (0.05 to 11.39)
Schleicher 2003 ⁵⁷	2/54	2/52		5.82	0.96 (0.14 to 6.59)
Healy 2004 ⁵⁴	0/23	6/43	←	3.01	0.14 (0.01 to 2.40)
Narayan 2006 ⁵⁶	1/29	0/32		2.47	3.30 (0.14 to 77.95)
Subtotal: I ² =14%, P=0.32	15/427	43/466	-	42.68	0.51 (0.24 to 1.06)
Quasirandomised trials					
Dorr 1986 ⁵⁰	2/39	4/50		7.41	0.64 (0.12 to 3.32)
Ravikumar 2000 ⁴⁶	6/91	22/89		16.15	0.27 (0.11 to 0.63)
Mouzopoulos 2008 ⁵¹	1/43	3/43		4.59	0.33 (0.04 to 3.08)
Subtotal: I ² =0%, P=0.65	9/173	29/182	-	28.15	0.32 (0.16 to 0.66)
Randomised trials					
Baker 2006 ⁴⁸	1/40	6/41		5.16	0.17 (0.02 to 1.36)
Keating 2006 ⁴⁵	6/69	6/111		12.67	1.61 (0.54 to 4.79)
Blomfeldt 2007 ⁴⁹	4/60	3/60		8.84	1.33 (0.31 to 5.70)
Macaulay 2008 ^{42 43}	1/17	0/23		2.50	4.00 (0.17 to 92.57)
Subtotal: I ² =30%, P=0.24	12/186	15/235	-	29.17	1.09 (0.40 to 2.99)
Overall: I ² =27%, P=0.16	36/786	87/883	-	100.00	0.57 (0.34 to 0.96)
		0	.01 0.05 0.2 1 5 20 1	00	
		Fa to re	vours Favou tal hip hemiarthroplas placement	irs sty	

Fig 2 | Random effects meta-analysis comparing relative risk of reoperation after total hip arthroplasty and hemiarthroplasty for displaced intracapsular hip fractures

carried out a systematic literature review and metaanalysis of all clinical studies that aimed for a head to head comparison of either implant. We investigated complication rates and mortality and determined whether similar differences in these events, if any, could be found in randomised trials and the wider body of non-experimental studies. We also summarised patient centred outcomes such as function and health related quality of life, and investigated variables that may contribute to the observed effects.

METHODS

Two reviewers (CH and DS) independently carried out a comprehensive search (last update 27 March 2010) of Medline, Embase, the Cochrane register of controlled trials, and publishers' databases for randomised controlled trials, quasirandomised trials, and cohort studies (both retrospective and prospective) that compared hemiarthroplasty with total hip arthroplasty for treating displaced femoral neck fractures in patients aged more than 60 years. We excluded registry data and case series—that is, studies that investigated either total hip arthroplasty or hemiarthroplasty for treating hip fractures.

We used medical subject headings (or their equivalents in other databases), including the following key search and wild card terms: hip, femoral neck, intraarticular, intra-articular, fracture*, surg*, hemi*, total*, bipolar, unipolar, arthroplast*, replacement, random*. Terms were connected by the Boolean operators "AND" and "OR".

Reviewers traced the bibliographies of all retrieved trials and other relevant publications, including reviews and meta-analyses, for citations missed by the

	Mean (SD) age (years)		Male pat	Male patients (%)		l preoperative risk fication	Cognitive and physical status prefracture	
Author	Total hip arthroplasty	Hemiarthro- plasty	Total hip arthroplasty	Hemiarthro- plasty	Total hip arthroplasty	Hemiarthroplasty	Total hip arthroplasty	Hemiarthroplasty
Baker 2006 ⁴⁸	74 (6)	76 (5)	20	22	Median ASA 2 (1-3)	Median ASA 2 (1-3)	Mini-mental score 10 (7- 10)	Mini-mental score 10 (9- 10)
Blomfeldt 2007 ⁴⁹	81 (5)	81 (5)	22	10	Ceder A/B 88%	Ceder A/B 83%	SPMSQ 9 (SD 1), ADL A/B: 97%	SPMSQ 9 (SD 1), ADL A/B: 98%
Dorr 1986 ⁵⁰	69 (9)	69 (12)	41	30	NS	NS	Oriented and ambulatory patients only	Oriented and ambulatory patients only
Eyssel 1994 ⁵²	78 (9)	84 (7)	9	21	Comorbidity 76%	Comorbidity 87%	Ambulatory 99%	Ambulatory 92%
Gebhard 1992 ⁵³	75	76	NS	NS	Mean ASA 3	Mean ASA 3	NS	NS
Healy 2004 ⁵⁴	80		NS	NS	NS	NS	NS	NS
Keating 2006 ⁴⁵	75 (6)	75 (7)	25	17	Comorbidity 80%	Comorbidity 70%	Oriented and ambulatory patients only	Oriented and ambulatory patients only
Levi 1996 ⁵⁵	80	80	22	22	NS	NS	NS	NS
Macaulay 2008 ⁴² 43	82 (7)	77 (9)	59	39	Mean No of comorbidities 4 (SD 2)	Mean No of comorbidities 4 (SD 3)	Oriented and ambulatory patients only	Oriented and ambulatory patients only
Mouzopoulos 2008 ⁵¹	73 (5)	74 (4)	24	29	Mean ASA 2 (SD 2)	Mean ASA 2 (SD 3)	Oriented and ambulatory patients only, mean SPMSQ 8 (SD 3)	Oriented and ambulatory patients only, mean SPMSQ 8 (SD 3)
Narayan 2006 ⁵⁶	59	63	NS	NS	NS	NS	NS	NS
Ravikumar 2000 ⁴⁶	81	82	10	10	No significant differe	ences in age, sex, preop	erative mobility, or comorbio	dity
Schleicher 2003 ⁵⁷	81 (12)	81 (10)	17	13	ASA 3/4 94%	ASA 3/4 91%	Ambulatory 91%	Ambulatory 100%
Squires 1999 ⁵⁸	69	71	12	6	NS	NS	Oriented and ambulatory patients only	Oriented and ambulatory patients only
Xu 2002 ⁵⁹	72 (5)	75 (6)	46	46	NS	NS	NS	NS
NS=Not specified.								

Table 3 Characteristics of patients included in individual studies

electronic search. See the web extra for a summary of the search strategy.

Selection process

Two reviewers (CH and DS) reviewed titles and abstracts first, and independently decided whether the papers potentially contained sufficient information. If deemed eligible by either reviewer, the full paper was obtained for a detailed review. We included studies published in languages that could be read and understood by the reviewers (English, German, Dutch, Swedish, French, Spanish, and Italian). Eligible studies compared hemiarthroplasty and total hip arthroplasty in a head to head fashion and provided sufficient numerical information on at least one of the following prespecified end points: reoperation for any cause, dislocation, deep infection, one year mortality, and any general perioperative complication (including nosocomial pneumonia and urinary tract infection, as well as a thromboembolic or cardiovascular event). General complications were handled as a composite end point. We also investigated function and health related quality of life (if assessed by valid scoring systems or questionnaires).

Data abstraction and assessment of methodological quality Two reviewers (CH and DS) independently abstracted data in duplicate, including general information (author, publication year), type of study, fracture classification, period of patient enrolment, mean patients' age, sex distribution, prefracture comorbidity, cognitive function and mobility, average length of followup, type of prosthesis, and use of bone cement. The **A** training database event rates with nominators and denominators for different end points, as well as means and standard deviations of functional score and quality of life assessments.

Three reviewers (CH, DS, and MW) independently assessed the methodological quality of papers according to the set of items used by Parker in two previous Cochrane reviews related to this subject.^{28 29} Quality criteria included concealment of allocation; description of entry criteria, demographic profiles, and outcomes; adherence to the intention to treat principle; blinding; handling of withdrawals; explanation of cointerventions; and a minimum follow-up of one year after surgery. The reviewers resolved disagreement by discussion.

Data analysis

We analysed binary end points (for example, reoperation and mortality) by calculating relative risks and corresponding risk differences. For differences in functional scores and quality of life instruments we calculated the weighted mean difference and the pooled

	No of events/ No in group							
	Treatment	Control	Relative risk	Weight	Relative risk			
Retrospective cohort stu	dies		(95%CI)	(70)	(95% CI)			
Gebhard 1992 ⁵³	1/44	6/122		5.73	0.46 (0.06 to 3.73)			
Eyssel 1994 ⁵²	2/213	4/150		8.67	0.35 (0.07 to 1.90)			
Squires 1999 ⁵⁸	2/32	1/43		4.53	2.69 (0.25 to 28.36)			
Xu 2002 ⁵⁹	1/32	2/24		4.59	0.38 (0.04 to 3.90)			
Schleicher 2003 ⁵⁷	1/54	1/52		3.36	0.96 (0.06 to 15.00)			
Narayan 2006 ⁵⁶	3/29	0/32		2.97	7.70 (0.41 to 143.00)			
Subtotal: I ² =0%, P=0.43	10/404	14/423	-	29.84	0.77 (0.31 to 1.92)			
Ouasirandomised trials								
Dorr 1986 ⁵⁰	7/39	2/50		10.61	4.49 (0.99 to 20.41)			
Ravikumar 2000 ⁴⁶	18/91	12/89	-	44.14	1.47 (0.75 to 2.87)			
Subtotal: I ² =43%, P=0.19	25/130	14/139	-	54.74	2.07 (0.75 to 5.69)			
Randomised trials								
Baker 2006 ⁴⁸	3/40	0/41		2.95	7.17 (0.38 to 134.53)			
Keating 2006 ⁴⁵	3/69	3/111		9.89	1.61 (0.33 to 7.75)			
Macaulay 2008 ^{42 43}	1/17	0/23		2.58	4.00 (0.17 to 92.57)			
Blomfeldt 2007 ⁴⁹	0/60	0/60		0.00	(Excluded)			
Subtotal: I ² =0%, P=0.64	7/186	3/235	-	15.41	2.47 (0.69 to 8.76)			
Overall: I ² =4%, P=0.40	42/720	31/797	•	100.00	1.48 (0.89 to 2.46)			
		0.	.01 0.05 0.2 1 5 20 10	00				
Favours Favours total hip hemiarthroplasty replacement								



standardised mean difference. In general, higher scores indicate better function—for example, the Harris hip score, the short form 36 (SF-36) physical component score, or the European quality of life instrument 5D (EQ-5D) visual analogue scale. We reversed the polarity of inverse scores (those producing higher values with poorer function, such as the Oxford hip score³⁰) by subtracting the maximum possible score from the observed score. In case authors provided ranges instead of standard deviations of means, we approximated the standard deviation by the rule of thumb range divided by 4.

To account for variability within and between studies we used the DerSimonian-Laird random effects approach to aggregate data.³¹ We assessed heterogeneity by using the I² statistic,³² with values more than 50% suggesting substantial variability between studies. Publication bias was evaluated by funnel plot asymmetry and Egger's linear regression test.³³ We assumed the presence of publication bias if the intercept of the regression line was significantly (P<0.1) away from the null.

We carried out stratified analyses for differences between the results from randomised trials and retrospective cohort studies and further differentiated between randomised trials with and without proper concealment of treatment allocation. To examine the impact of individual patient and study criteria we planned the following additional two way sensitivity analyses a priori: balanced patient profile given published information on personal details, comorbidity and ambulation (yes or no); inclusion of mobile and oriented patients only (yes or heterogeneous sample/ unclear); cementation of stems in the hemiarthroplasty group (100% or <100%, or unclear); follow-up interval less than or more than 24 months; intention to treat analysis specified (yes or no); specification of surgeon grades in the study (yes or no); less than 5% loss to follow-up (yes or no, or not specified); and postoperative care specified (yes or no). We compared treatment effects between independent subgroups using the test for interaction proposed by Altman and Bland,34 providing both P values and ratios of relative risks with 95% confidence intervals. For all calculations we used Stata 10.0 statistical software, incorporating the updated metan meta-analysis package.35

RESULTS

The electronic search strategy revealed 3821 papers, 160 of which were potentially relevant to the analysis. An additional search of the reference lists yielded 42 citations not covered by the electronic search. A short-list of 24 papers was compiled from the set of 202 full text articles retrieved. At this stage, the reviewers omitted another nine manuscripts. Two studies, one of which was published in German and later duplicated in English, included patients with trochanteric fractures only, as did a study from Belgium.³⁶⁻³⁸

Another two studies enrolled patients with femoral neck and trochanteric fractures but did not provide sufficient information to enable separate analyses on both factors.^{39 40} One study that compared primary joint replacement with internal fixation did not distinguish between subgroups who had undergone hemiarthroplasty and total hip arthroplasty.⁴¹

Two randomised trials were reported in duplicate.⁴²⁻⁴⁵ The related publications were assessed for overlapping and unique information relevant to this review. Finally, one study represented the 13 year follow-up of patients enrolled in an earlier randomised trial but had different authors.⁴⁶⁴⁷

For studies available in duplicate, references to the most recent publication were provided. This left 15 original reports (fig 1) of four randomised trials, three quasirandomised trials, and eight retrospective cohort studies, enrolling a total of 1890 patients.

Study characteristics

Tables 1-3 summarise the key characteristics of the included studies, and table 4 the criteria of methodological quality. In seven studies (n=776) patients were randomly allocated to hemiarthroplasty or to total hip arthroplasty.^{43 45 46 48-51} Concealed randomisation (sealed envelopes or a central automated telephone system) was guaranteed by four trials, all of which met most other quality criteria.^{43 45 48 49} In the remaining studies, patients were assigned to one of the procedures by admission numbers,⁵⁰ day of the week,⁴⁶ or in a fixed, alternating sequence.⁵¹ Only one study stated blinded outcome assessment.⁵¹

Table 4 Methodological quality of included studies

Table 4 Methodolog	gical quality of	included stud	ies							
Study	Conceal- ment of allocation	Entry criteria specified	Intention to treat analysis	Intervention groups characterised	Surgeon grade specified	Postopera- tive care	Outcome measures defined	Outcome assessor blinded	Follow-up period of ≥ 1 year	Missing information on <5% of patients
Baker 2006 ⁴⁸	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes
Keating 2006 ⁴⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Blomfeldt 2007 ⁴⁹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Macaulay 2008 ^{42 43}	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No
Dorr 1986 ⁵⁰	No	Yes	No	Yes	No	Yes	Yes	No	Yes	Yes
avikumar 2000 ⁴⁶	No	Yes	No	No	Yes	Yes	Yes	No	Yes	No
Nouzopoulos 2008 ⁵¹	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
Gebhard 1992 ⁵³	No	No	No	No	No	No	Yes	No	Yes	No
Eyssel 1994 ⁵²	No	No	No	Yes	Yes	Yes	Yes	No	No	No
evi 1996 ⁵⁵ .	No	No	No	No	Yes	Yes	Yes	No	No	No
Squires 1999 ⁵⁸	No	Yes	No	Yes	Yes	No	Yes	No	Yes	Yes
(u 2002 ⁵⁹	No	No	No	No	No	No	No	No	Yes	No
Schleicher 2003 ⁵⁷	No	No	No	Yes	No	No	Yes	No	Yes	Yes
lealy 2004 ⁵⁴	No	No	No	No	No	No	Yes	No	Yes	Yes
Varayan 2006 ⁵⁶	No	Yes	No	No	No	Yes	Yes	No	Yes	No

Experimental evidence was supplemented by data from eight retrospective cohort studies (n=1114) of low methodological quality.⁵²⁻⁵⁹ The number of fulfilled quality criteria ranged from one to seven of a maximum 12. However, two of these observational studies together included 584 patients, or one third of the entire sample of participants.5255

	No of events/ No in group					
	Treatment	Control	Relative risk	Weight	Relative risk	
Retrospective cohort stu	ıdies		(3376 CI)	(70)	(9978 CI)	
Gebhard 1992 ⁵³	1/44	1/122		6.22	2.77 (0.18 to 43.39)	
Eyssel 1994 ⁵²	1/213	0/150		4.61	2.12 (0.09 to 51.61)	
Levi 1996 ⁵⁵	2/98	5/123		17.96	0.50 (0.10 to 2.53)	
Schleicher 2003 ⁵⁷	1/54	0/52		4.66	2.89 (0.12 to 69.40)	
Xu 2002 ⁵⁹	0/32	0/24		0.00	(Excluded)	
Subtotal: I ² =0%, P=0.60	5/441	6/471	-	33.44	1.07 (0.33 to 3.51)	
Quasirandomised trials						
Ravikumar 2000 ⁴⁶	2/91	3/89		15.09	0.65 (0.11 to 3.81)	
Dorr 1986 ⁵⁰	0/39	0/50		0.00	(Excluded)	
Subtotal: Not applicable	2/130	3/139		15.09	0.65 (0.11 to 3.81)	
Randomised trials						
Baker 2006 ⁴⁸	3/40	1/41		9.53	3.08 (0.33 to 28.34)	
Keating 2006 ⁴⁵	3/69	4/111	_	21.87	1.21 (0.28 to 5.23)	
Blomfeldt 2007 ⁴⁹	3/60	2/60		15.30	1.50 (0.26 to 8.66)	
Macaulay 2008 ^{42 43}	1/17	0/23		4.76	4.00 (0.17 to 92.57)	
Subtotal: I ² =0%, P=0.85	10/186	7/235	-	51.47	1.71 (0.66 to 4.45)	
Overall: I ² =0%, P=0.89	17/757	16/845	-	100.00	1.27 (0.64 to 2.51)	
		0	.01 0.05 0.2 1 5 20 10	00		
		Fav tot rej	vours Favou al hip hemiarthroplas olacement	irs ity		

Fig 4 | Random effects meta-analysis comparing relative risk of deep infections after total hip arthroplasty and hemiarthroplasty for displaced intracapsular hip fractures

operative care (n=9). Loss to follow-up was less than a fo 5% in seven of the 15 studies, and hemiarthroplasty of stems were cemented in six. Information on intention to treat analysis was provided in four studies: either all the patients were analysed according to the allocated intervention,^{45 49} or the paper confirmed that all patients had undergone the assigned procedure.4351

According to seven studies, 43 45 48 49 52 57 59 total hip replacement lengthened the duration of surgery by an average of 11 minutes (95% confidence interval 4 tog 19 minutes). Heterogeneity was significant for the > reported lengths of surgery (I²=71%, P=0.002).

Reoperation rates

The seven randomised trials and seven of eight retro spective cohort studies, totalling 1669 patients and 123 events, provided data on reoperation rates. Overall, o primary total hip arthroplasty was associated with a lower risk of subsequent reoperation compared with hemiarthroplasty (fig 2). The pooled relative risk was **5** 0.57 (95% confidence interval 0.34 to 0.96), equalling a risk difference of 4.4% (95% confidence interval 0.2% to 8.5%) in favour of total hip replacement. Heterogeneity across studies was low (I²=27%, P=0.16). Publication bias was not evident (intercept 0.79, P=0.36).

Table 5 shows the influence of the study design and other prespecified variables on relative risks of reoperation. Studies with follow-up intervals of two years or longer were associated with bigger treatment effects in favour of total hip replacement (ratio of relative risks 0.44, 95% confidence interval 0.15 to 1.26, test for interaction, P=0.13). Treatment effects were comparable between retrospective cohort and experimental studies (1.26, 0.42 to 3.79, test for interaction, P=0.67) but seemed to be overestimated by studies with

Variables	No of trials/ No of patients	Relative risk (95% CI)	Relative risk ratio (95% CI)	z	P value*
Design:					
Randomised or quasirandomised	7/776	0.63 (0.29 to 1.40)			
Retrospective cohort	7/893	0.50 (0.23 to 1.08)	1.26 (0.42 to 3.79)	0.42	0.67
Concealment:					
Appropriate	4/421	1.08 (0.39 to 3.03)			
Unclear	10/1248	0.41 (0.25 to 0.68)	2.59 (0.83 to 8.07)	1.65	0.10
Baseline characteristics:					
Balanced	12/1240	0.55 (0.30 to 1.01)			
Unbalanced	2/429	0.56 (0.10 to 3.15)	0.98 (0.15 to 6.09)	-0.01	0.99
Patient sample:					
Oriented and ambulatory	10/1201	0.75 (0.41 to 1.38)		2.14	
Mixed	4/468	0.27 (0.13 to 0.56)	2.80 (1.09 to 7.22)		0.03
Hemiarthroplasty type:					
All cemented stems	6/866	0.88 (0.44 to 1.73)		4.97	
Mixed	8/803	0.37 (0.20 to 0.68)	2.35 (0.95 to 5.82)	1.86	0.06
Follow-up:					
≥2 years	12/1186	0.47 (0.26 to 0.86)			
<2 years	2/483	1.05 (0.45 to 2.45)	0.44 (0.15 to 1.26)	-1.51	0.13
Surgeon grade:					
Specified	7/1039	0.59 (0.26 to 1.33)			
Not specified	7/630	0.52 (0.23 to 1.21)	- 1.13 (0.35 to 3.57)	0.21	0.83
Intention to treat:					
Respected	4/426	1.32 (0.60 to 2.90)			
Not specified	10/1243	0.40 (0.24 to 0.67)		2.47	0.01
Losses to follow-up					
<5%	7/737	0.60 (0.28 to 1.30)			
Not specified	7/932	0.51 (0.24 to 1.11)	- 1.17 (0.39 to 3.48)	0.29	0.77
Postoperative care					
Specified	8/1036	0.54 (0.30 to 0.96)			
Not specified	6/633	0.55 (0.18 to 1.64)	0.98 (0.28 to 3.37)	-0.02	0.98
*Derived from test of interaction. ³⁴					

Table 5 Sensitivity analysis showing influence of prespecified variables on relative risks of reoperation

	No in group							
	Treatment	Control	Relative risk (95% CI)	Weight (%)	Relative risk (95% CI)			
Retrospective cohort stu	dies		(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	()	(////			
Gebhard 1992 ⁵³	7/44	20/122		8.18	0.97 (0.44 to 2.14)			
Eyssel 1994 ⁵²	81/213	77/150	=	23.62	0.74 (0.59 to 0.93)			
Squires 1999 ⁵⁸	5/32	2/43		2.61	3.36 (0.70 to 16.22)			
Schleicher 2003 ⁵⁷	33/54	29/52	÷.	20.25	1.10 (0.79 to 1.51)			
Subtotal: I ² =55%, P=0.08	3 126/343	128/367	+	54.66	0.96 (0.67 to 1.37)			
Randomised trials								
Baker 2006 ⁴⁸	16/40	9/41	-	9.82	1.82 (0.91 to 3.64)			
Keating 2006 ⁴⁵	14/69	16/111		10.59	1.41 (0.73 to 2.70)			
Blomfeldt 2007 ⁴⁹	6/60	5/60		4.66	1.20 (0.39 to 3.72)			
Macaulay 2008 ^{42 43}	15/17	16/23	÷	20.28	1.27 (0.92 to 1.75)			
Subtotal: I ² =0%, P=0.82	51/186	46/235	•	45.34	1.35 (1.04 to 1.75)			
Overall: I ² =54%, P=0.03	177/529	174/602	•	100.00	1.14 (0.87 to 1.48)			
		0.	01 0.05 0.2 1 5 20 10	00				
Favours Favours total hip hemiarthroplasty								

No of events/

Fig 5 | Random effects meta-analysis comparing relative risk of general complications after total hip arthroplasty and hemiarthroplasty for displaced intracapsular hip fractures inadequate or unclear concealment of allocation (2.59, 0.83 to 8.07, test for interaction, P=0.10).

The observed benefit in reoperation rates with total hip replacement mitigated in studies that had enrolled only oriented and ambulatory patients, used only cemented stems for hemiarthroplasty, and respected the intention to treat principle (table 5).

Local and general complications

Dislocation rates were reported in 12 studies (1517 patients, 73 events). Effect sizes were homogeneous ($I^2=4\%$, P=0.40) and publication bias was not evident (intercept 1.43, P=0.24). The pooled analysis (fig 3) showed no significant difference in the risk for dislocation between total hip arthroplasty and hemiarthroplasty (relative risk 1.48, 95% confidence interval 0.89 to 2.46, risk difference 1.0%, 95% confidence interval -1.2% to 3.2%). A tendency was, however, noted towards a higher risk for dislocation after total hip arthroplasty among randomised and quasirandomised trials. This trend was most pronounced in studies with balanced patient baseline profiles and follow-up intervals of two or more years (table 6).

Variables	No of trials/ No of patients	Relative risk (95% CI)	Relative risk ratio (95% CI)	z	P value*
Design:					
Randomised or quasirandomised	6/690	1.87 (1.08 to 3.25)			
Retrospective cohort	6/827	0.77 (0.30 to 1.92)	2.43 (0.83 to 7.10)	1.63	0.10
Concealment:					
Appropriate	4/421	2.46 (0.69 to 8.76)			
Unclear	8/1096	1.30 (0.66 to 2.57)	1.88 (0.44 to 7.93)	0.87	0.39
Baseline characteristics:					
Balanced	11/1154	1.67 (1.02 to 2.73)			
Unbalanced	1/363	0.35 (0.06 to 1.89)	4.75 (0.82 to 27.57)	1.74	0.08
Patient sample:					
Oriented and ambulatory	9/1115	1.99 (0.93 to 4.27)			
Mixed	3/402	1.14 (0.56 to 2.32)	1.74 (0.61 to 4.92)	1.05	0.29
Hemiarthroplasty type:					
All cemented stems	5/800	0.91 (0.27 to 3.02)			
Mixed	7/717	1.73 (1.01 to 2.97)	0.52 (0.14 to 1.95)	-0.95	0.34
Follow-up:					
≥2 years	10/1034	1.67 (1.02 to 2.73)			
<2 years	2/483	0.35 (0.06 to 1.89)	4.75 (0.82 to 27.48)	1.74	0.08
Surgeon grade:					
Specified	7/1039	1.43 (0.83 to 2.47)			
Not specified	5/478	1.47 (0.44 to 4.91)	— 0.97 (0.25 to 3.63)	0.00	1.00
Intention to treat:					
Respected	3/340	1.93 (0.47 to 7.87)			
Not specified	9/1177	1.41 (0.72 to 2.75)	— 1.36 (0.28 to 6.46)	0.39	0.70
Losses to follow-up					
<5%	6/651	2.67 (1.10 to 6.49)			
Not specified	6/866	1.04 (0.47 to 2.26)	2.56 (0.78 to 8.37)	1.57	0.12
Postoperative care					
Specified	7/950	1.58 (0.63 to 3.93)			
Not specified	5/567	1.36 (0.51 to 3.63)	1.15 (0.30 to 4.39)	0.21	0.83
*Derived from test of interaction. ³⁴					

Table 6 | Sensitivity analysis showing influence of prespecified variables on relative risks of dislocation

Deep infections occurred in 33 of 1264 patients enrolled in 11 studies. There was no heterogeneity (I²=0%, P=0.89) but evidence of funnel plot asymmetry (intercept 2.81, P=0.027) for this end point. The pooled relative risk of infection after total hip arthroplasty compared with hemiarthroplasty was 1.27 (95% confidence interval 0.64 to 2.51), translating into a risk difference of 0.4% (95% confidence interval -0.7% to 1.6%). Results were virtually similar among experimental, quasiexperimental, and retrospective cohort studies (fig 4). Also, no substantial interaction was noted between all investigated subgroups for this end point (table 7).

General complications were observed slightly more often after total hip arthroplasty than after hemiarthroplasty (relative risk 1.14, 95% confidence interval 0.87 to 1.48, risk difference 3.7%, 95% confidence interval -3.7% to 11.1%). This trend was consistently observed in randomised trials (fig 5) as well as in studies with balanced patient baseline profiles and follow-up intervals of two or more years (table 8). Results were prone to publication bias (intercept 4.09, P=0.033).

One year mortality

Nine studies (1023 patients, 178 events) provided data on one year mortality. There was no evidence of heterogeneity (I²=0%, P=0.85) and publication bias (intercept 0.22, P=0.76). Altogether, mortality did not differ between patients undergoing total hip arthroplasty and hemiarthroplasty (relative risk 0.92, 95% confidence interval 0.70 to 1.21, risk difference 1.4%, 95% confidence interval -2.6% to 5.4%). Notable benefits were observed in randomised trials (fig 6); however, the test for interaction did not reveal significant differences between subgroups (table 9).

Function and health related quality of life

The Harris hip score was used for outcome assessment in three randomised trials and in 246 patients, with follow-up intervals ranging from 12 to 48 months.⁴³⁴⁹⁵¹ This score contains the subscales pain, function, deformity, and range of motion, and may achieve values from 0 to 100 points, with higher scores indicating better function.⁶⁰ Total hip replacement was consistently associated with better function in all studies (I²=4%,

Variables	No of trials/ No of patients	Relative risk (95% CI)	Relative risk ratio (95% CI)	z	P value*
Design:					
Randomised or quasirandomised	6/690	1.37 (0.59 to 3.18)			
Retrospective cohort	5/912	1.07 (0.32 to 3.51)	= 1.28 (0.29 to 5.47)	0.33	0.74
Concealment:					
Appropriate	4/421	1.71 (0.65 to 4.44)			
Unclear	7/1181	0.91 (0.34 to 2.46)	1.86 (0.47 to 7.34)	0.89	0.38
Baseline characteristics:					
Balanced	9/1018	1.52 (0.69 to 3.31)			
Unbalanced	2/584	0.67 (0.15 to 2.85)	2.25 (0.43 to 11.63)	0.97	0.33
Patient sample:					
Oriented and ambulatory	7/979	1.81 (0.75 to 4.36)		1.27	
Mixed	4/623	0.72 (0.24 to 2.17)			0.20
Hemiarthroplasty type:					
All cemented stems	5/800	1.61 (0.61 to 4.19)			
Mixed	6/802	0.98 (0.36 to 2.62)	= 1.64 (0.41 to 6.47)	0.71	0.48
Follow-up:					
≥2 years	8/898	1.52 (0.63 to 3.64)			
<2 years	3/704	0.93 (0.30 to 2.83)	1.63 (0.39 to 6.74)	0.69	0.49
Surgeon grade:					
Specified	7/1185	1.14 (0.55 to 2.37)			
Not specified	4/417	2.82 (0.35 to 22.5)	- 0.40 (0.04 to 3.67)	-0.80	0.42
Intention to treat:					
Respected	3/340	1.49 (0.51 to 4.31)			
Not specified	8/1262	1.12 (0.45 to 2.75)	- 1.33 (0.33 to 5.36)	0.41	0.68
Losses to follow-up:					
<5%	5/576	1.65 (0.63 to 4.31)			
Not specified	6/1026	0.95 (0.35 to 2.54)	= 1.74 (0.44 to 6.87)	0.79	0.43
Postoperative care:					
Specified	7/1110	1.02 (0.43 to 2.44)		0.70	
Not specified	4/492	1.79 (0.58 to 5.50)	0.57 (0.13 to 2.35)	-0.78	0.44
*Derived from test of interaction.34					

Table	7 Sensitivity	/ analysis showing	influence of	prespecified	variables or	n relative risks o	of deep infection
IUDIC	JULIAN	<i>unuty</i> 313 3110 ming	S IIIII CIICC OI	prespectited			

P=0.35) (fig 7), and without evidence of publication bias (intercept -0.18, P=0.95). The weighted mean difference in favour of total hip replacement was 5.4 (95% confidence interval 2.7 to 8.2).

Another trial⁴⁵ had utilised the hip rating questionnaire, an instrument consisting of the four subscales arthritis, pain, walking, and daily function. Scores may range from 16 to 100 points.⁶¹ At final follow-up after 24 months, the weighted mean difference was 6.1 (95% confidence interval 0.4 to 11.8) in favour of total hip replacement.

The Oxford hip score was used for functional outcome measurement in another trial.⁴⁸ This score ranges from 12 to 60 points, with higher values indicating poorer function.⁶² After three years of follow-up, hip function after total hip arthroplasty was rated slightly better than after hemiarthroplasty, by 3.5 points (95% confidence interval -0.7 to 7.7 points).

The standardised mean difference from all trials was estimated at 0.42 (95% confidence interval 0.24 to 0.61), indicating a medium functional benefit of total hip replacement.⁶³

SF-36 physical component scores were available from two trials totalling 121 patients, ^{43 48} with no differences between total hip arthroplasty and hemiarthroplasty (weighted mean difference 1.9, 95% confidence interval –2.2 to 6.0). Another trial had used EQ-5D utility scores, which were rated significantly better in the total hip arthroplasty group compared with the hemiarthroplasty group after two years of follow-up (mean difference 0.16, 95% confidence interval 0.05 to 0.27).⁴⁵

DISCUSSION

The purpose of this review was to provide additional insight into the options for treating intracapsular hip fractures, focusing on the role of total hip replacement now that there is a significant body of evidence indicating that older patients treated with arthroplasty of all types have fewer complication rates and better health outcomes than those treated with internal fixation. Total hip arthroplasty compared with hemiarthroplasty was found to be beneficial for reoperation rates and functional outcomes. It is unclear whether patients

Variables	No of trials/ No of patients	Relative risk (95% CI)	Relative risk ratio (95% CI)	z	P value*
Design:					
Randomised or quasirandomised	4/421	1.35 (1.04 to 1.75)			
Retrospective cohort	4/710	0.95 (0.67 to 1.36)	— 1.41 (0.91 to 2.19)	1.54	0.12
Concealment:					
Appropriate	4/421	1.35 (1.04 to 1.75)			
Unclear	4/710	0.95 (0.67 to 1.36)	1.41 (0.91 to 2.19)	1.54	0.12
Baseline characteristics:					
Balanced	7/768	1.24 (1.02 to 1.51)			
Unbalanced	1/363	0.74 (0.58 to 0.93)	1.68 (1.24 to 2.27)	3.37	<0.01
Patient sample:					
Oriented and ambulatory	7/965	1.16 (0.86 to 1.56)		0.43	
Mixed	1/166	0.97 (0.44 to 2.13)	1.20 (0.51 to 2.78)		0.67
Hemiarthroplasty type:					
All cemented stems	4/744	1.14 (0.68 to 1.93)		-0.11	0.92
Mixed	4/387	1.18 (0.95 to 1.47)	0.96 (0.55 to 1.70)		
Follow-up:					
≥2 years	6/648	1.24 (1.02 to 1.51)			
<2 years	2/483	0.75 (0.60 to 0.94)	1.65 (1.22 to 2.23)	3.27	<0.01
Surgeon grade:					
Specified	6/859	1.22 (0.83 to 1.80)			
Not specified	2/272	1.07 (0.79 to 1.45)	— 1.13 (0.69 to 1.85)	0.52	0.60
Intention to treat:					
Respected	3/340	1.28 (0.97 to 1.70)			
Not specified	5/791	1.08 (0.74 to 1.58)	— 1.18 (0.73 to 1.89)	0.70	0.48
Losses to follow-up:					
<5%	5/562	1.26 (0.97 to 1.63)		1.07	
Not specified	3/569	0.95 (0.62 to 1.48)			0.28
Postoperative care:					
Specified	3/564	1.09 (0.56 to 2.11)			
Not specified	5/567	1.20 (0.98 to 1.48)	0.90 (0.45 to 1.80)	-0.28	0.78
*Derived from test of interaction.34					
					-

Table 8 | Sensitivity analysis showing influence of prespecified variables on relative risks of general complications

undergoing total hip replacement may also benefit from a small survival advantage after one year. The potential advantages must be traded off against a possible higher risk of dislocation and general complications, higher invasiveness, and longer theatre times.

Strengths and weaknesses of this review

This is the first review to compile all available head to head investigations of total hip arthroplasty compared with hemiarthroplasty for femoral neck fractures. By including both experimental and non-experimental studies, the sample size and robustness of estimates was enhanced compared with previous reviews. Yet, the number of available studies was small, and with an overall sample size of fewer than 2000 patients our results do not allow for conclusive statements on the effectiveness of total hip arthroplasty and hemiarthroplasty for treating femoral neck fractures.

Some might argue about the inclusion of retrospective cohort studies because of their inherent risk of bias. However, such studies enrolled a significant number of patients and, despite methodological limitations, ignoring this source of data might have affected the external validity of our findings. The researchers and spossible from the available papers. We tried to con-9, and since trol our computations for confounding, carried out various sensitivity analyses, and explored the interaction between subgroups.

There is no doubt that only randomisation creates biologically similar patient cohorts, in which unknown confounders are equally distributed, and allows for inferences on causal relations between exposure and outcome. It might be assumed that in non-randomised studies, patients with poorer prognosis were more likely to undergo the faster, less invasive procedure of hemiarthroplasty, thereby introducing selection and differential indication bias.

Although the published information on patient profiles was limited in quantity and quality, participants enrolled in the retrospective cohort studies were not entirely different from those enrolled in the randomised trials. This is not surprising, since the typical patient presenting with a femoral neck fracture to an emergency department in an industrial country (thus being a potential candidate for a clinical study) is a

Variables	No of trials/No of patients	Relative risk (95% CI)	Relative risk ratio (95% CI)	z	P value*
Design:					
Randomised or quasirandomised	6/695	0.8 (0.56 to 1.14)		-1.19	0.24
Retrospective cohort	3/328	1.11 (0.73 to 1.71)	0.71 (0.41 to 1.24)		
Concealment:					
Appropriate	3/340	0.67 (0.29 to 1.50)		-0.81	0.42
Unclear	6/683	0.95 (0.71 to 1.27)	0.70 (0.29 to 1.65)		
Baseline characteristics:					
Balanced	9/1023	0.91 (0.69 to 1.20)		_	_
Unbalanced	0	_			
Patient sample:					
Oriented and ambulatory	6/621	0.88 (0.57 to 1.37)			0.84
Mixed	3/402	0.93 (0.66 to 1.32)	— 0.94 (0.53 to 1.66)	-0.20	
Hemiarthroplasty type:					
All cemented stems	3/356	0.84 (0.40 to 1.77)		-0.24	0.81
Mixed	6/667	0.93 (0.69 to 1.24)	— 0.90 (0.40 to 2.02)		
Follow-up:					
≥2 years	8/903	0.90 (0.68 to 1.19)		-0.51	0.61
<2 years	1/120	1.33 (0.31 to 5.70)	— 0.67 (0.15 to 2.98)		
Surgeon grade:					
Specified	4/520	0.79 (0.51 to 1.22)		-0.83	0.41
Not specified	5/503	1.01 (0.70 to 1.43)	- 0.79 (0.45 to 1.37)		
Intention to treat:					
Respected	4/426	0.72 (0.42 to 1.23)		-1.02	0.31
Not specified	5/597	1 (0.72 to 1.37)	- 0.72 (0.38 to 1.34)		
Losses to follow-up:					
<5%	5/581	0.93 (0.59 to 1.47)		0.12	0.90
Not specified	4/442	0.90 (0.64 to 1.27)	- 1.03 (0.58 to 1.82)		
Postoperative care:					
Specified	5/531	0.87 (0.60 to 1.26)		-0.32	
Not specified	4/492	0.96 (0.59 to 1.54)	0.90 (0.49 to 1.65)		0.75
*Derived from test of interaction. ³⁴					

Table 9 | Sensitivity analysis showing influence of prespecified variables on relative risks of one year mortality

woman in her mid-70s with osteoporosis, cardiovascular comorbidity, and associated drugs. The available information did not support the thesis that different treatment assignment in non-randomised studies was mainly based on preoperative risk assessment. Although we do not discount this, we suspect that in these studies surgeons' preferences, as well as disposability of teams, hardware, and theatre time slots, contributed to the decision to implant a total hip or a bipolar prosthesis. This does, however, resemble clinical reality.

We noted further interesting patterns of treatment effects that may be useful for planning future trials. Random assignment to interventions in itself had little influence on the reported reoperation rates. In fact, the observed advantage with total hip replacement disappeared with adequate concealment of allocation, which may be an important surrogate of higher methodological quality. Other features such as the recruitment of physically and mentally fit patients and routine cementation of stems in the hemiarthroplasty control group mitigated (but still did not exclude) favourable reoperation risks after total hip arthroplasty. Upcoming trial protocols should respect these important variables that may distort effect sizes. They must also aim for minimum follow-up intervals of two years to confirm or refute potential gains of total hip arthroplasty over hemiarthroplasty in the fracture scenario.

It is noteworthy that, although derived from a small subset of studies, the findings of better hip function after total hip replacement were highly consistent. A reliable trade-off of the possible benefits and harms with total hip replacement also requires large scale data on health related quality of life.

Other studies

A recent meta-analysis of randomised trials identified three studies,⁶⁴ all included in this review.^{45,46,50} The meta-analysis reported similar findings to this review, with higher reoperation rates and a trend for lower dislocation rates with hemiarthroplasty. Patients who had undergone total hip replacement were more likely to become mobile and less likely to require a second analgesic at 1, 2, 4, and 13 years, although this was not statistically significant at any assessment time. The greater proportion of mobile patients who had

	No of events/ No in group				
	Treatment	Control	Relative risk (95% CI)	Weight (%)	Relative risk (95% CI)
Retrospective cohort stu	ıdies		(******	()	(******
Gebhard 1992 ⁵³	14/44	38/122	+	29.00	1.02 (0.62 to 1.70)
Xu 2002 ⁵⁹	4/32	3/24		3.80	1.00 (0.25 to 4.06)
Schleicher 2003 ⁵⁷	10/54	6/52		8.46	1.60 (0.63 to 4.10)
Subtotal: I ² =0%, P=0.69	28/130	47/198	•	41.26	1.12 (0.73 to 1.71)
Quasirandomised trials					
Dorr 1986 ⁵⁰	3/39	4/50		3.60	0.96 (0.23 to 4.05)
Ravikumar 2000 ⁴⁶	21/91	24/89	-	28.89	0.86 (0.52 to 1.42)
Mouzopoulos 2008 ⁵¹	10/43	13/43		14.86	0.77 (0.38 to 1.56)
Subtotal: I ² =0%, P=0.95	34/173	41/182	-	47.35	0.83 (0.56 to 1.24)
Randomised trials					
Keating 2006 ⁴⁵	4/69	11/111		6.10	0.58 (0.19 to 1.76)
Blomfeldt 2007 ⁴⁹	4/60	3/60		3.52	1.33 (0.31 to 5.70)
Macaulay 2008 ^{42 43}	1/17	5/23		1.77	0.27 (0.03 to 2.11)
Subtotal: I ² =0%, P=0.43	9/146	19/194	-	11.39	0.67 (0.30 to 1.50)
Overall: I ² =0%, P=0.85	71/449	107/574	•	100.00	0.92 (0.70 to 1.21)
		0	.01 0.05 0.2 1 5 20 10	00	
		Fav tot rej	rours Favou al hip hemiarthroplas placement	irs sty	



undergone total hip replacement seems to correspond to the better hip function found with total hip replacement in this review. An earlier Cochrane review²⁸ that compared cemented and cementless arthroplasty and internal fixation also carried out a meta-analysis of total hip arthroplasty compared with hemiarthroplasty based on three studies used in this review.454750 The Cochrane review found no significant differences between the interventions, although there was a trend for higher dislocation rates and lower reoperation rates with total hip replacement. Also, total hip arthroplasty was found to take about 20 minutes longer than hemiarthroplasty.

Meaning of our review

The optimal treatment strategy for hip fractures matters to healthcare professionals, policy makers, and payers of healthcare services, and should avoid costly reoperations, secondary hospital admissions, loss of independence, and physical disability. The noted 43% relative or 4% absolute reduction in the risk of reoperation with total hip arthroplasty is clinically important, given reported baseline risks of revision with hemiarthroplasty ranging from 6% to 18%.²¹²³ It must be kept in mind, however, that this is an aggregated effect mainly driven by data from trials with inadequate concealment. In contrast, total hip replacement was associated with a 48% relative or 1% absolute increase in the risk of dislocation. Avoiding further major surgical procedures is particularly relevant to patients with hip fractures, who are generally older and less healthy than the general population.

Considering the upper and lower confidence limits, it is possible that the reduction in the risk of reoperation may be smaller than the theoretical increase in the risk of dislocation. Under these circumstances, total hip replacement may still be the dominant treatment strategy, as dislocation can be managed on an outpatient basis and is a less serious event than reoperation. Also, the direct costs for a bipolar head in hemiarthroplasty may exceed those for a cemented polyethylene cup in total hip arthroplasty.

In this review, total hip replacement was not associated with a higher risk of deep infections, and a slightly higher risk of general complications did not result in higher mortality. Thus the procedure may be 8 considered effective and safe in patients with intracapsular hip fractures, and a reasonable alternative to hemiarthroplasty.

We believe that the consistently better functional **n** in the consistently better functional **n** in the consistent is the consistent of th outcome ratings after total hip replacement are the most relevant findings of this review. However, the observed mean difference of 5.4 points in the total Harobserved mean difference of 5.4 points in the total Har-ris hip score remains difficult to interpret, since no minimal important difference has currently been standardised mean difference derived from all five stu-dies that had used at least one validated disease specific questionnaire was 0.42, suggesting a medium treat-ment effect.⁶³ Unanswered questions and future research The results from this review cannot be considered con-clusive owing to various interactions between strata. A Furthermore, the improvement in function and health outcomes with total hip replacement was modest and only reported by a small number of studies. Therefore

only reported by a small number of studies. Therefore large scale clinical research to study the potential effects of total hip replacement on mobility and regain **>** of independent living after displaced fractures of the femoral neck is merited. The quantitative findings from this review may allow for a better planning of those trials, selection of trial end points, and sample \overline{a} size estimation.

Patients are currently being recruited to the Hip o Fracture Evaluation with Alternatives of Total Hip Arthroplasty versus Hemi-Arthroplasty trial, an initiative of the International Hip Fracture Research Collaborative. With a target sample size of 2500 patients for this study, the results from this trial, expected to be **D** published in 2011, may allow for more conclusive inferences on this matter, but still must be interpreted **2** in the light of current best evidence and the prior probability of effectiveness with either type of joint replacement. Additionally, a formal health economic analysis would be useful for providing greater clarity in decision making.

Patients with greater levels of activity treated with hemiarthroplasty may induce osteoarthritis more rapidly than in less active patients and, as they are likely to have a higher life expectancy, will be exposed to the risk of acetabular erosion for a longer period. Factors contributing to dislocation rates may be the

BMJ: first published as 10.1136/bmj.c2332 on 11 June 2010. Downloaded from https://www.bmj.com/ on Protected by copyright, including for uses related to text and data mining, Al tr

including

mining,

1 9 June 2 training, tra

and

simi

ilar technologies

2025 at Department GEZ-LTA Erasmushogeschool

by copyright,



Fig 7 | Random effects meta-analysis comparing weighted mean differences of Harris hip scores after total hip arthroplasty and hemiarthroplasty for displaced intracapsular hip fractures

> surgical approach and the size of the prosthetic head. A multivariable analysis of dislocation after primary total hip replacement for all diagnoses found that a posterolateral approach and a smaller prosthetic head were associated with a higher rate of dislocation.65 Apart from choosing the optimal hardware, improving the surgical access route may help to reduce complications with this common procedure.

Conclusion

Although this review was limited to a small number of randomised controlled trials and retrospective cohort studies, some evidence suggested that patients treated with total hip arthroplasty for intracapsular hip fractures may have better outcomes than those treated with hemiarthroplasty.

The data currently available, however, do not yet allow for definitive conclusions about the scale and existence of some of the identified treatment effects, owing to varying interactions between subgroups, particularly those concerning random allocation of patients. Considering that a more frequent use of total hip replacement in oriented and mobile patients with displaced intracapsular hip fractures may be appropriate and save costs in the long run, an adequately powered trial is urgently needed to dispel these remaining doubts of the benefit to risk ratio with total hip replacement in the fracture setting.

WHAT IS ALREADY KNOWN ON THIS TOPIC

Arthroplasty is associated with lower reoperation rates and better function than internal fixation for patients with displaced intracapsular hip fractures

Total hip arthroplasty may be associated with better function than hemiarthroplasty in this setting and may also avoid secondary conversion surgery

A sample of randomised trials comparing both interventions was included in a recent systematic review, but an overview of the entire body of evidence is lacking

WHAT THIS STUDY ADDS

Data from 15 studies suggest that total hip arthroplasty is associated with lower reoperation rates and slightly better functional outcomes than hemiarthroplasty

Advantages with total hip arthroplasty must be traded off against a slightly higher risk of dislocations and general complications

Large well designed clinical trials comparing the two interventions are required before a definitive conclusion on their risk-benefit ratio can be reached

Funding All authors are independent of funders except CH who is an employee of DePuy International, a manufacturer of hip arthroplasty prostheses, which may have a financial interest in the results of this review

Competing interests: All authors have completed the Unified Competing Interest form at www.icmie.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) CH has support from DePuy International a Johnson & Johnson company for the submitted work; (2) DS, AE, and MW have no relationships with DePuy International a Johnson & Johnson Company that might have an interest in the submitted work in the previous three years; (3) their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and (4) CH, DS, AE, and MW have no non-financial interests that may be relevant to the submitted work.

Ethical approval: Not required.

Data sharing: The technical appendix, and datasets extracted from individual papers and meta-analyses are available from the corresponding author at chopley@its.jnj.com.

- Dorner T, Weichselbaum E, Lawrence K, Viktoria SK, Rieder A. 1 Austrian osteoporosis report: epidemiology, lifestyle factors, public health strategies. Wien Med Wochenschr 2009;159:221-9.
- 2 Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010;21:399-408.
- Eklund F, Nordstrom A, Neovius M, Svensson O, Nordstrom P. 3 Variation in fracture rates by country may not be explained by differences in bone mass. Calcif Tissue Int 2009;85:10-6.
- 4 Abrahamsen B, Vestergaard P. Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporos Int 2010;21:373-80.
- 5 Sirois MJ, Cote M, Pelet S. The burden of hospitalized hip fractures: patterns of admissions in a level I trauma center over 20 years. / Trauma 2009;66:1402-10.
- Holt G, Smith R, Duncan K, Hutchison JD, Reid D. Changes in 6 population demographics and the future incidence of hip fracture. Injury 2009;40:722-6.
- Icks A, Haastert B, Wildner M, Becker C, Rapp K, Dragano N, et al. Hip fractures and area level socioeconomic conditions: a populationbased study. BMC Public Health 2009;9:114.
- 8 Dodds MK, Codd MB, Looney A, Mulhall KJ. Incidence of hip fracture in the Republic of Ireland and future projections: a population-based study. Osteoporos Int 2009;20:2105-10.
- Tsang SW, Kung AW, Kanis JA, Johansson H, Oden A. Ten-year fracture probability in Hong Kong southern Chinese according to age and BMD femoral neck T-scores, Osteoporos Int 2009:20:1939-45.
- 10 Fisher AA, O'Brien ED, Davis MW. Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy. Bone 2009;45:246-53.
- Oliver D, Connelly JB, Victor CR, Shaw FE, Whitehead A, Genc Y. et al. 11 Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and metaanalyses, BMI 2007:334:82-5
- Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, 12 Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. IAMA 2005:293:2257-64.
- 13 Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB. Bazemore MG. Zee RY. et al. Effect of Vitamin D on falls: a metaanalysis, IAMA 2004:291:1999-2006.
- 14 Iwamoto I, Sato Y, Takeda T, Matsumoto H, Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging 2008:3:483-9.
- 15 Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD004523.
- 16 Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD003376.
- Reid IR, Bolland MJ, Grey A. Effect of calcium supplementation on hip 17 fractures. Osteoporos Int 2008;19:1119-23.
- 18 MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of

treatments to prevent fractures in men and women with low bone density or osteoporosis. *Ann Intern Med* 2008;148:197-213.

- 19 Jackson C, Gaugris S, Sen SS, Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. *Q J Med* 2007;100:185-92.
- 20 Sahni S, Hannan MT, Gagnon D, Blumberg J, Cupples LA, Kiel DP, et al. Protective effect of total and supplemental vitamin C intake on the risk of hip fracture—a 17-year follow-up from the Framingham Osteoporosis Study. Osteoporos Int 2009;20:1853-61.
- 21 Rogmark C, Johnell O. Primary arthroplasty is better than internal fixation of displaced femoral neck fractures: a meta-analysis of 14 randomized studies with 2,289 patients. *Acta Orthop* 2006;77:359-67.
- 22 Frihagen F, Nordsletten L, Madsen JE. Hemiarthroplasty or internal fixation for intracapsular displaced femoral neck fractures: randomised controlled trial. *BMJ* 2007;335:1251-4.
- 23 Bhandari M, Devereaux PJ, Swiontkowski MF, Tornetta P III, Obremskey W, Koval KJ, et al. Internal fixation compared with arthroplasty for displaced fractures of the femoral neck: a metaanalysis. J Bone Joint Surg Am 2003;85-A:1673-81.
- 24 Scottish Intercollegiate Guidelines Network. Management of hip fracture in older people: a national clinical guideline. Scottish Intercollegiate Guidelines Network, 2009.
- 25 Kakar S, Tornetta P III, Schemitsch EH, Swiontkowski MF, Koval K, Hanson BP, et al. Technical considerations in the operative management of femoral neck fractures in elderly patients: a multinational survey. J Trauma 2007;63:641-6.
- 26 Bhandari M, Devereaux PJ, Tornetta P III, Swiontkowski MF, Berry DJ, Haidukewych G, et al. Operative management of displaced femoral neck fractures in elderly patients: an international survey. J Bone Joint Surg Am 2005;87:2122-30.
- 27 Sayana MK, Lakshmanan P, Peehal JP, Wynn-Jones C, Maffulli N. Total hip replacement for acute femoral neck fracture: a survey of National Joint Registries. *Acta Orthop Belg* 2008;74:54-8.
- 28 Parker MJ, Gurusamy K. Arthroplasties (with and without bone cement) for proximal femoral fractures in adults. *Cochrane Database Syst Rev* 2006;3:CD001706.
- 29 Parker MJ, Handoll HH. Replacement arthroplasty versus internal fixation for extracapsular hip fractures in adults. *Cochrane Database Syst Rev* 2006;2:CD000086.
- 30 Dawson J, Fitzpatrick R, Frost S, Gundle R, McLardy-Smith P, Murray D. Evidence for the validity of a patient-based instrument for assessment of outcome after revision hip replacement. *J Bone Joint* Surg Br 2001;83:1125-9.
- 31 DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177-88.
- 32 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
- 33 Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-34.
- 34 Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;326:219.
- 35 Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC. Metan: fixed- and random-effects meta-analysis. *Stata J* 2008;8:3-28.
- 36 Geiger F, Schreiner K, Schneider S, Pauschert R, Thomsen M. [Proximal fracture of the femur in elderly patients. The influence of surgical care and patient characteristics on post-operative mortality.] Orthopade 2006;35:651-7.
- 37 Geiger F, Zimmermann-Stenzel M, Heisel C, Lehner B, Daecke W. Trochanteric fractures in the elderly: the influence of primary hip arthroplasty on 1-year mortality. *Arch Orthop Trauma Surg* 2007;127:959-66.
- 38 Haentjens P, Casteleyn PP, Opdecam P. Primary bipolar arthroplasty or total hip arthroplasty for the treatment of unstable intertrochanteric and subtrochanteric fractures in elderly patients. *Acta Orthop Belg* 1994;60(suppl 1):124-8S.
- 39 Dzupa V, Bartonicek J, Skala-Rosenbaum J, Prikazsky V. [Mortality in patients with proximal femoral fractures during the first year after the injury.] Acta Chir Orthop Traumatol Cech 2002;69:39-44.
- 40 Hussain A, Prasad KS. Mortality among elderly patients with fracture of the hip. *JK Pract* 2003;10:4-9.
- 41 Broos PL, Stappaerts KH, Luiten EJ, Gruwez JA. Endoprosthesis: the best way to treat unstable intracapsular hip fractures in elderly patients. *Unfallchirurg* 1987;90:347-50.
- 42 Macaulay W, Nellans KW, Iorio R, Garvin KL, Healy WL, Rosenwasser MP. Total hip arthroplasty is less painful at 12 months compared with hemiarthroplasty in treatment of displaced femoral neck fracture. *HSS J* 2008;4:48-54.
- 43 Macaulay W, Nellans KW, Garvin KL, Iorio R, Healy WL, Rosenwasser MP. Prospective randomized clinical trial comparing hemiarthroplasty to total hip arthroplasty in the treatment of

displaced femoral neck fractures: winner of the Dorr award. *J Arthroplasty* 2008;23:2-8.

- 44 Keating JF, Grant A, Masson M, Scott NW, Forbes JF. Displaced intracapsular hip fractures in fit, older people: a randomised comparison of reduction and fixation, bipolar hemiarthroplasty and total hip arthroplasty. *Health Technol Assess* 2005;9:iii-x, 1.
- 45 Keating JF, Grant A, Masson M, Scott NW, Forbes JF. Randomized comparison of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. Treatment of displaced intracapsular hip fractures in healthy older patients. *J Bone Joint Surg Am* 2006;88:249-60.
- 46 Ravikumar KJ, Marsh G. Internal fixation versus hemiarthroplasty versus total hip arthroplasty for displaced subcapital fractures of femur—13 year results of a prospective randomised study. *Injury* 2000;31:793-7.
- 47 Skinner P, Riley D, Ellery J, Beaumont A, Coumine R, Shafighian B. Displaced subcapital fractures of the femur: a prospective randomized comparison of internal fixation, hemiarthroplasty and total hip replacement. *Injury* 1989;20:291-3.
- 48 Baker RP, Squires B, Gargan MF, Bannister GC. Total hip arthroplast and hemiarthroplasty in mobile, independent patients with a displaced intracapsular fracture of the femoral neck: a randomized controlled trial. J Bone Joint Surg Am 2006;88:2583-9.
- 49 Blomfeldt R, Tornkvist H, Eriksson K, Soderqvist A, Ponzer S, Tidermark J. A randomised controlled trial comparing bipolar hemiarthroplasty with total hip replacement for displaced intracapsular fractures of the femoral neck in elderly patients. J Bone Joint Surg Br 2007;89:160-5.
- Dorr LD, Glousman R, Hoy AL, Vanis R, Chandler R. Treatment of femoral neck fractures with total hip replacement versus cemented and noncemented hemiarthroplasty. *J Arthroplasty* 1986;1:21-8.
 Mouzopoulos G, Stamatakos M, Arabatzi H, Vasiliadis G, Batanis K, M, Arabatzi H, Vasiliadis G, Batanis K, M, Arabatzi H, Vasiliadis G, Batanis K, M, Arabatzi H, Vasiliadis K, M, Arabatzi H, Vasil
- 51 Mouzopoulos G, Stamatakos M, Arabatzi H, Vasiliadis G, Batanis G Tsembeli A, et al. The four-year functional result after a displaced subcapital hip fracture treated with three different surgical options. *Int Orthop* 2008;32:367-73.
- 52 Eyssel M, Schwenk W, Badke A, Krebs S, Stock W. [Total endoprosthesis or dual head prosthesis in endoprosthetic management of femoral neck fractures?] *Unfallchirurg* 1994;97:347-52.
- 53 Gebhard JS, Amstutz HC, Zinar DM, Dorey FJ. A comparison of total hip arthroplasty and hemiarthroplasty for treatment of acute fracture of the femoral neck. *Clin Orthop Relat Res* 1992;123-31.
- 54 Healy WL, Iorio R. Total hip arthroplasty: optimal treatment for displaced femoral neck fractures in elderly patients. *Clin Orthop Relat* a *Res* 2004;43-8.
- 55 Levi N. Early mortality after cervical hip fractures. *Injury* 1996;27:565-7.
- 56 Narayan KK, George T. Functional outcome of fracture neck of femur treated with total hip replacement versus bipolar arthroplasty in a South Asian population. Arch Orthop Trauma Surg 2006;126:545-8.
- 57 Schleicher I, Kordelle J, Jurgensen I, Haas H, Melzer C. [Femoral neck fractures in the elderly—bipolar hemiarthroplasty in total hip replacement.] Unfallchirurg 2003;106:467-71.
- 58 Squires B, Bannister G. Displaced intracapsular neck of femur fractures in mobile independent patients: total hip replacement or hemiarthroplasty? *Injury* 1999;30:345-8.
- 59 Xu X, Liu Y, Liu J, Li Y. Prosthetic replacement in treatment of subcapital femoral neck fractures in the elderly. *Chin J Traumatol* 2002;5:28-31.
- 60 Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. *J Bone Joint Surg Am* 1969;51:737-55.
- 61 Johanson NA, Charlson ME, Szatrowski TP, Ranawat CS. A selfadministered hip-rating questionnaire for the assessment of outcome after total hip replacement. J Bone Joint Surg Am 1992;74:587-97.
- 62 Dawson J, Fitzpatrick R, Murray D, Carr A. Comparison of measures to assess outcomes in total hip replacement surgery. *Qual Health Care* 1996;5:81-8.
- 63 Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. *Psychol Bull* 1995;117:167-78.
- 64 Goh SK, Samuel M, Su DH, Chan ES, Yeo SJ. Meta-analysis comparing total hip arthroplasty with hemiarthroplasty in the treatment of displaced neck of femur fracture. J Arthroplasty 2009;24:400-6.
- 65 Berry DJ, von Knoch M, Schleck CD, Harmsen WS. Effect of femoral head diameter and operative approach on risk of dislocation after primary total hip arthroplasty. J Bone Joint Surg Am 2005;87:2456-63.

Accepted: 12 April 2010